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Background: Using information technology for medication management is an opportunity to help physicians to
improve the quality of their documentation and communication and ultimately to improve patient care and patient
safety. Physician education is necessary to take full advantage of information technology systems. In this trial, we
seek to determine the effectiveness of an intensive educational intervention compared with the standard approach
in improving information technology–mediated medication management and in reducing potential adverse drug
events in the outpatient clinic.
Methods/Design: We are conducting a multicenter, cluster randomized controlled trial. The participants are
specialists and residents working in the outpatient clinic of internal medicine, cardiology, pulmonology, geriatrics,
gastroenterology and rheumatology. The intensive educational intervention is composed of a small-group session
and e-learning. The primary outcome is discrepancies between registered medication (by physicians) and actually
used medication (by patients). The key secondary outcomes are potential adverse events caused by missed
drug–drug interactions. The primary and key secondary endpoints are being assessed shortly after the educational
intervention is completed. Sample size will be calculated to ensure sufficient power. A sample size of 40 physicians
per group and 20 patients per physician will ensure a power of >90 %, which means we will need a total of 80
physicians and 1,600 patients.
Discussion: We performed an exploratory trial wherein we tested the recruitment process, e-learning, time schedule,
and methods for data collection, data management and data analysis. Accordingly, we refined the processes and
content: the recruitment strategy was intensified, extra measures were taken to facilitate smooth conductance of the
e-learning and parts were made optional. First versions of the procedures for data collection were determined. Data
entry and analysis was further standardized by using the G-standard database in the telephone questionnaire.
Trial registration: ISRCTN registry: ISRCTN50890124. Registered 10 June 2013.
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Treating patients with medication is one of the core ac-
tivities of physicians in the outpatient clinics of internal
medicine and related specialties. Unfortunately, adverse
drug events (ADEs) frequently occur in this setting [1,
2]. Patients are often treated simultaneously for more
than one medical condition, by more than one physician,
with more than one drug and use various pharmacies to
obtain prescribed and non-prescribed medications. This
may result in scattering of information about the pa-
tient’s previous and actual medication use and allergies.
One of the causes of ADEs is a discrepancy between
what the physician thinks the patient is taking and what
the patient is actually taking at home [3]. To prevent these
discrepancies and resulting medical consequences, medi-
cation should be appropriately managed by physicians in
the outpatient setting. This includes appropriate docu-
mentation of the medication, appropriate communication
to other health care providers and engaging patients in
management of their own medication [4, 5].
Using information technology (IT) for medication
management is an opportunity to support physicians to
improve the quality of their documentation and com-
munication and ultimately to reduce ADEs. IT for
medication management refers to the combination of
computerized physician order entry (CPOE) and clin-
ical decision support systems.
To stimulate the improvement of quality of care by use
of IT, “meaningful use” criteria are used in the United
States. With respect to CPOE, these criteria include
maintaining an active medication and allergy list for
each patient and providing all patients with a copy of
their medication information [4]. In the Netherlands, a
guideline, “handover of medication information between
care settings”, has come into force [6]. This guideline
advises physicians to be aware of which medications the
patient is taking and to provide patients with a printed
overview of their current medications, recent changes
and the reasons therefor.
Education of users (that is, physicians) is necessary to
improve medication management and to take full advan-
tage of IT systems. In addition, inappropriate use of IT
may lead to new kinds of errors [6].
The objective of the present study is to determine the
effectiveness of an intensive educational intervention com-
pared with the usual approach in improving IT-mediated
medication management and in reducing ADEs in the
outpatient clinic. This objective pertains to the cluster
(physician) level.
Methods/Design
The Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 guidelines were used
to write the study protocol [7] We are conducting atwo-arm cluster randomized superiority trial, with a 1:1
allocation ratio in two academic hospitals. Physicians
are the unit of allocation. The intervention is targeted
on the cluster (physician) level.
Physicians are randomly allocated either to the control
group, who have already received the “usual approach”,
or the intervention group, who also have already received
the usual approach and now will receive an additional in-
tensive educational intervention. Randomization will be
done by using a computerized system with randomly per-
mutated blocks. A small block size of six clusters per block
will be chosen because the clusters are recruited and
randomized sequentially. Randomization will be strati-
fied by hospital to balance the influence of the geo-
graphic areas, work environments and IT systems of the
two hospitals [8].
A cluster randomization design was adopted because
the intervention is at the level of the physician and there
is a risk of contamination at the level of the physician.
Physicians trained in a new technique will find it difficult
to revert to an old technique at the toss of a coin. Allow-
ing physicians to deliver similar care to similar patients
ensures that the trial is following typical clinical practice
more closely [8].Setting
The study will be conducted in outpatient settings of in-
ternal medicine departments and related specialties and
subspecialties at two academic hospitals in the Netherlands:
University Medical Center Utrecht (UMCU) and Erasmus
University Medical Center Rotterdam (EMC). The study is
focused on internal medicine physicians because pharma-
cotherapy is their core treatment option.
CPOE systems are available in the two participating
hospitals. UMCU uses the ChipSoft hospital information
system (ChipSoft BV, Amsterdam, the Netherlands), in
which the CPOE is fully integrated into the electronic
health record. EMC uses a CPOE system called iSoft Med-
icator (Computer Sciences Corp (CSC), Groningen, the
Netherlands), which is partly integrated into the electronic
health record. Both CPOE systems meet the basic re-
quirements of CPOE systems, which are ability to store
a current medication list and allergies and basic decision
support (drug–drug interaction, dose, duplicate order,
contraindications) [9].
The ethical review boards of both academic hospitals
reviewed the protocol and declared that this research
does not fall under the Dutch legislation for research on
human subjects, because of its limited burden on partici-
pating patients. The ethical review board of the Dutch
organization of medical education approved the protocol
and telephone questionnaire with respect to scientific
content and accuracy.
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and time line
Inclusion criteria for physicians
 Specialists and residents of internal medicine
(including general internal medicine, nephrology,
endocrinology, infectious diseases, oncology,
hematology, vascular medicine, inherited and
metabolic diseases, and acute internal medicine),
cardiology, pulmonology, geriatrics, gastroenterology
and rheumatology
 Physicians with consultations in the outpatient clinic
for at least 4 hours per week
Exclusion criterion for physicians
 Physicians who were involved in the development of
the intensified educational intervention being
investigated
Inclusion criteria for patients
 Patients older than 18 years of age
 Patients visiting the outpatient clinic consulting a
physician who is participating in the study
Exclusion criteria for patients
 Patients who are unable to understand and speak
Dutch or English
 Patients who have insufficient understanding of their
medications to answer questions about their
medicine, or patients who do not have a caregiver
who can answer the questions
Physicians are recruited by giving a talk about the
study in a meeting with eligible physicians. During the
talk, physicians are given the information letter, and they
are asked to participate in the study. They are asked to
sign a consent form if they decide to participate. Physi-
cians in the intervention and control groups will receive
the same information letter and informed consent form.
Physicians in our study are not fully informed about the
measurements of the (patient-related) outcomes, because
this information could influence the behavior of partici-
pants in the control group. This approach was subject to
the approval provided by the ethical review board.
Consecutive patients who visit a participating physician
for an outpatient consultation during the enrollment
period are asked in a telephone questionnaire to give in-
formation about their medication use, and they are asked
to give permission for access to their medical records.
There will be two ways of asking patients to partici-
pate: by a research assistant present in the waiting roomor by medical assistants. To avoid physicians’ changing
their behavior because they know patients are included,
the inclusion process is as non-intrusive as possible.
When patients immediately agree to participate, they
sign the informed consent right away. Patients who con-
sider participation will be called in the week ahead. If
they agree to participate, they are asked to return the in-
formed consent by mail.
In our study, the physician represents the cluster. The
intervention is targeted on the physician who cares for
individual patients. This holds that patients are not able
to avoid a treatment of a physician who received or did
not receive the intervention. However, they are able to
choose whether to participate in the telephone question-
naire and whether to give us permission for access to
their medical record.
To ensure a representative sample of patients per phys-
ician, no more than five patients per day per physician will
be asked to participate. To minimize the chance of interim
changes in their medications, patients will be called as
soon as possible, with a maximum lapse of 2 weeks after
the index visit at the outpatient clinic.
Participant flow is illustrated in Fig. 1. The measure-
ments for the primary and key secondary outcomes will
take place in groups of physicians to allow for flexible
planning. After completion of the educational interven-
tion, consecutive patients of these physicians will be in-
vited to participate in the study. The enrollment period is
also flexible because of the variations in numbers of pa-
tients a particular physician sees in the outpatient clinic.
Electronic assessment of knowledge and skills will be
carried out in three groups to allow for approximately
equal time between randomization and assessment. The
intervention group will be assessed at a time point
approximately 6 months after completing the educa-
tional intervention. The control group will be assessed
at a time point approximately 6 months after the median
number of months whereafter the intervention was com-
pleted after randomization by physicians in the interven-
tion group, with the control assessment time point being
the median number of months between randomization
and completion of education by intervention group plus
6 months).
Blinding
Physicians are randomly allocated right after inclusion
by the investigator, following the assignment generated
by the computer system. As the assignment for the next
allocation is provided at the moment of randomization, al-
location is sufficiently concealed. Of course, the interven-
tion itself is not blinded to the participating physicians.
Patients are blinded to the intervention status of their
physicians. Physicians are not fully informed about the na-
ture of the patient-related outcome measures. Researchers
Fig. 1 Patient flow through the trial
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tion status of the physicians. Research assistants are aware
of the intervention status of physicians, but they are not
knowledgeable about the content of the educational inter-
vention. The researcher who is analyzing the data does
not collect the data. Data analysis will be undertaken
blinded to study arm allocation; that is, the control and
intervention will be identified only as “A” and “B” until
analysis is complete.
Intervention
Usual approach as control
In the context of this study, the usual approach is the in-
struction that is currently given when IT for medication
management is made available to physicians. Usually,
classroom instruction consisting of a lecture demon-
strating the main features of the system is offered, andlimited opportunities for practical exercises exist. In this
study, the usual approach was not standardized between
hospitals and physicians.
Usual approach plus intensive educational intervention
In addition to the usual instruction, physicians in the inter-
vention arm will receive an intensive educational interven-
tion consisting of a small-group session and e-learning.
Physicians will attend a small-group session with discus-
sions on the advantages and disadvantages of IT-mediated
medication management to establish mutual agree-
ments between professionals about how the medication
management task is properly performed. There will be
also opportunities to share experiences, ask questions
and discuss cases. There will be approximately eight
physicians in the group session, which will last approxi-
mately 1 hour.
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the expected benefits and limits of IT to adequately cali-
brate their trust in IT and form an appropriate attitude
toward IT. A social norm will be set for effective and
safe IT-mediated management by role modeling of ex-
perts on video. The training is built up from easy to dif-
ficult cases to promote self-efficacy. Physicians are given
step-by-step procedural instructions and information to
support problem solving. The training will be tailored
because it is self-directed. Physicians may choose their
starting level, to practice a case again, to practice a spe-
cific self-chosen part of a task again or to go on to the
next level of difficulty. This part of the intervention will
be individually delivered as e-learning modules devel-
oped according to the four-component instructional de-
sign (4C/ID) model [10]. The 4C/ID model allows for
research-based design of educational interventions. The
e-learning is generic, but specific procedures in CPOE
are tailored to the actual local CPOE system in use [11].
To stimulate adherence to the intensive educational
intervention, physicians in the intervention group receive
several reminders. Earning continuing medical education
credits when both the small-group session and the e-
learning modules are finished further stimulates adherence.Outcomes
Primary outcome: medication discrepancies
Differences between the two study arms are analyzed
using as the primary outcome the proportion of medica-
tion discrepancies per physician. Medication discrepancies
are defined as discrepancies between medications regis-
tered by physicians in CPOE and medications actually
used by patients, obtained by the telephone questionnaire.
Each discrepancy is counted; that is, any patient can con-
tribute multiple discrepancies.
The following events are taken into account:
 Omission in registration of the current medication: A
drug is taken by the patient but is not registered in
the list of medications in CPOE
 Addition in the registration of the current
medication: A drug is not used by the patient but is
registered in CPOE.
Discrepancies in dosing (dose per intake and number
of intakes per unit of time) are not taken into account.
The proportion of discrepancies is then calculated using
(1) the number of discrepancies (omissions and additions)
as the numerator and (2) the sum of the number of dis-
crepancies and the number of medications a patient is tak-
ing and the number of medications registered in CPOE
minus the overlap as the denominator. Thus, no medica-
tion is counted twice in the denominator.The proportion of discrepancies will also be deter-
mined and analyzed, restricted to high-risk medications
specifically. The high-alert medication list of the Insti-
tute for Safe Medication Practices will be used to indi-
cate high-risk medications [12].
The data collected by means of the telephone ques-
tionnaire are considered the gold standard for the pa-
tient’s use of medication and past ADEs. The telephone
questionnaire is derived from the structured medica-
tion history [5], the telephone questionnaire used by
Gandhi et al. [1] and Consumer Quality Index ques-
tions tailored for individual patient experiences in
health care [13]. A prior version of the telephone ques-
tionnaire was validated against the medication history
obtained during home visits. Improvements were made
accordingly.
Data collectors are medical students or medical doc-
tors in the phase just before or after their graduation or
should be experienced research nurses. Data collectors
are trained in two ways. First, there is a standard oper-
ating procedure (SOP) describing how exactly the ques-
tionnaire should be carried out and what to do in
various circumstances (for example, when a caregiver
answers the questions). Second, data collectors work
their first day together with an experienced data col-
lector and have opportunities to practice and receive
feedback.
The telephone questionnaire will be made available at
the trial website only after completion of data collection
to ensure blinding of participating physicians for the
outcome measures involved [14]. Data managers extract
the following data from the CPOE systems: medication
on the index date and registered ADEs.Key secondary outcome: missed drug–drug interactions
with potential for causing harm
The key secondary outcome is any difference between
the two study arms in the proportion of patients per phys-
ician with at least one missed drug–drug (DD) interaction
with potential for causing an ADE (PADEs) per physician.
Whether there is a DD interaction with potential for an
ADE is assessed by following the Dutch clinical guidelines
for management of DD interactions using the G-standard
database. The G-standard is the Dutch drug database,
which is used by all Dutch parties in health care, including
physicians, pharmacists, manufacturers, health insurers
and the government. The G-standard supports the dif-
ferent processes in health care, such as, among others,
decision support on DD interactions. Also, information
is given about the (published) effect of the interaction.
The G-standard categorizes the effects of the interac-
tions into six levels of severity ranging from A (minor)
to F (potentially lethal) [15].
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Discrepancies in adverse drug events Differences be-
tween the two study arms in the proportion of patients
with at least one missed ADEs per physician are de-
fined as discrepancies between the registration of
ADEs in CPOE versus the information regarding ADEs
obtained from the patient via the telephone question-
naire. We take into account the ADEs with moderate
or severe potential consequences. The European Medi-
cines Agency guideline will be used to assess the sever-
ity of the ADE [16].
Use of computerized physician order entry Physicians’
use of CPOE will be registered with log files of the
CPOE systems to assess whether physicians meet the of-
ficial meaningful use criteria [4]. Also, additional criteria
were formulated to assess meaningful use. The following
aspects will be assessed:
 The number of lines inserted in CPOE per week
(numerator) divided by the number of patients
scheduled for outpatient consultation per week
(denominator)
 The number of allergies inserted in CPOE per week
(numerator) divided by the number of patients
scheduled for outpatient consultation per week
(denominator)
 The number of complete ADE registrations
(medication, symptoms, severity) inserted in CPOE
per week (numerator) divided by the number of
ADEs inserted in CPOE per week (denominator)
 The number of prescriptions with unspecified doses
in CPOE (numerator) divided by the number of
lines inserted in CPOE per week (denominator)
(In the numerator, we will exclude medication
obliged to be prescribed this way, because doses are
adjusted to frequent measurements, such as insulin
and vitamin K antagonists.)
CPOE use will be logged 2 months before the interven-
tion, during the intervention and until 6 months after the
intervention. These data will give an indication whether
the intervention remains effective over a longer period of
time (that is, retention of learning).
Data derived from the telephone questionnaire supports
the analysis of the physicians’ adherence to the Dutch
guidelines regarding handover of medication information
between care settings by calculating the difference be-
tween study arms in the following terms:
 Proportion of patients who were actively asked for
their use of medication during the consultation
 Proportion of patients who were given a printed
medication overview at the end of the consultationKnowledge and skills
With an assessment after the intervention period, physi-
cians’ knowledge and skills regarding IT-mediated medi-
cation management will be measured. To ensure content
validity of the assessment, a test matrix is used to guaran-
tee an even distribution of training content in the ques-
tions. The checklist for constructing written test questions
for basic and clinical sciences will be used to ensure high-
quality questions [17]. An expert team of an educator,
pharmacist, clinical pharmacologist and internist will be
asked to review the questions and propose improve-
ments. The distinctiveness of the assessment will be de-
termined by asking an expert and a naive end user to
pretest the assessment. Improvements will be made ac-
cording to the findings.
Patient-related outcomes
Patient-related outcomes will be analyzed on the basis of
the data derived from the telephone questionnaire by cal-
culating the difference between study arms in terms of
 Patients’ satisfaction with their care regarding their
medications
 Patients’ sense of responsibility to self-manage their
medications
Sample size calculation
For the sample size considerations, the following assump-
tions are made. Per specialist and per period, the same
number of patients are followed. The primary outcome is
the percentage of discrepancies between medication re-
cords and patient information. The design is a cluster
(physician) randomized trial with proportions as out-
comes. The comparison between groups should be able
to detect a difference of at least 10 % (from 70 % to 80 %
and from 80 % to 90 %), and testing is done at a signifi-
cance level of 5 % (two-sided) for each contrast. The
intraclass correlation coefficient is assumed to be 0.1,
following the method of Schnipper et al. [18]. To ensure
sufficient power, a sample per group of 40 physicians and
20 patients will ensure a power of >90 % for a total
of 80 physicians and 1,600 patients. If (substantially)
more physicians can be recruited, this may lead us to
recruit fewer patients while maintaining power.
Statistical methods
Descriptive statistics
We will use baseline characteristics of hospitals, physi-
cians and patients according to covariates known from
the literature or anticipated covariates, including, among
others, physician’s age, sex, years of experience in pre-
scribing and computer literacy, as well as patient’s num-
ber of medications [18–21].
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The primary analyses will be focused on comparing the
two study arms with regard to the proportions of discrep-
ancies and resulting PADEs. The unit of analysis is the
cluster (physicians). The analysis will follow the intent-to-
treat principle, including all physicians in the analysis as
randomized. However, physicians who do not contribute
any patients (and hence contribute no observations) will
be excluded from the analysis. No imputation of resulting
missing values will be done.
The primary outcome per patient is the proportion of
discrepancies, as defined above. A full regression model
appropriate to the structure of the data could be applied.
However, the proportions as defined most likely cannot
be modeled as binomial quantities, but a continuous ap-
proximation may be sufficiently adequate if the average
proportion per cluster (physician) is analyzed. This ana-
lysis is somewhat less efficient than a full model (if that
can be correctly specified), but cluster effects are appro-
priately included in the error term. Hence, this linear
model will be used to analyze the data (potentially appro-
priately transformed if model evaluation so indicates).
The population-averaged model with inclusion of the
covariate can be written algebraically as follows:
Yijh ¼ þ xi þ zh þ eijh;
where i is the intervention arm, j is the cluster (physi-
cians), h is the Hospital, Yijh indicates the value of the
average outcome for the ith treatment arm from the jth
physician of hospital h, α is the constant, β is the effect
size of the intervention, xi indicates the intervention arm
(value 1 = intervention arm, value 0 = control arm), zh
indicates the categorical covariate (hth hospital), and eijh
is the residual for jth physician in treatment arm i and
hospital h.
The analysis of secondary endpoints is exploratory and
will follow the same analytical approach used for the pri-
mary endpoint. Because of the exploratory nature of the
analysis, no type I error correction for multiplicity will
be done.
Data management
The data are collected by telephone and entered at the
core coordinating center (UMCU) in Research Online 2
(RO2). RO2 is an electronic data capture system that will
be used for data collection. Integrity is enforced when
data entry takes place in the web-based case report forms
by means of checks on value ranges, logical checks (for ex-
ample, the interview date cannot be later than the actual
date of interview), skip rules preventing unnecessary data
collection and coded answering options. To ensure analogy
between data entry in RO2 and CPOE, the G-standard
database is implemented in RO2.RO2 data traffic over the Internet is encrypted using
secured data communication protocols. Dedicated data-
bases and web servers are hosted in data centers that meet
the highest available standards for security (XS4ALL data
center, Diemen, the Netherlands: https://www.xs4all.nl/).
Access to and exporting of the RO2 data are limited to
data management staff of the Julius Center of UMCU,
who are not involved in the conduct of the trial. The pa-
tients’ data are coded, and the linking codes are stored
in separate password-protected locations. The data will
be prepared for analysis and stored on a secure server
within the IT facilities at UMCU. Access to the specific
folders on this server containing the research data is kept
to a minimum and granted only to researchers who are
specified by the principal investigator. Data will be locked
at the end of the study and securely stored for 15 years.
Only after the principal investigator has granted permis-
sion the data will be allowed to be unlocked.
Files with patient-related data will be sent from one
academic center to the core coordinating center. These
files will be sent using FileSender (SURFnet: https://
filesender.surfnet.nl/), a specially secured way to send
data with passwords. Files are zipped and encrypted be-
fore sending.
Discussion
We performed an exploratory trial wherein we tested
the following:
1. Recruitment process
2. Technical smoothness of the e-learning
3. Physicians’ reactions to the e-learning
4. Potential room for improvement regarding the
primary outcome
5. Appropriateness of the time schedule
6. Data collection methods
7. Data management
8. Categorization of medication and interaction
discrepancies
We refined the processes and content according to
our findings as follows:
1. We intensified the recruitment strategy.
2. We gave special warnings for certain systems
hindering the smoothness of e-learning and
introduced the possibility of carrying out the first
module together with the research physician.
3. Physicians were mostly positive, but they found the
e-learning too long. Therefore, we made some of the
content of the e-learning optional.
4. It turned out that there was enough potential room
for improvement, because only 37 % of the
medication records in the exploratory trial were
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physicians reported their intent to change their
behavior regarding IT-mediated medication
management or had already changed their behavior.
5. Physicians needed more time to finish the e-learning.
6. First versions of the SOPs for data collection were
determined.
7. Data entry was further standardized by using the
G-standard database in the telephone questionnaire.
8. Improvements in categorization were made, mostly
with the automation of the categorization process.
Trial status
Trial recruitment was completed on 1 January 2015.
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